Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
NCT07284459 is registered in ClinicalTrials.gov with Contineum Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
- Lead sponsor
- Contineum Therapeutics
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- January 8, 2026
- Completion date
- June 30, 2028
- Enrollment
- 324 (estimated)
- Sites
- 93
Conditions
As the registry lists them; a condition with its own page is linked.